Mitochondrial pathway-mediated apoptosis is associated with erlotinib-induced cytotoxicity in hepatic cells

Area of Science:

• Pharmacology
• Hepatology
• Molecular Biology

Background:

• Advanced non-small-cell lung cancer (NSCLC) with EGFR mutations is treated with EGFR tyrosine kinase inhibitors like erlotinib.
• Erlotinib can cause liver injury (hepatotoxicity), raising safety concerns.
• Understanding the mechanism of erlotinib-induced hepatotoxicity is crucial for developing protective strategies.

Purpose of the Study:

• To investigate the mechanism underlying erlotinib-induced hepatotoxicity in vitro.
• To provide experimental evidence for screening potential hepatoprotective compounds against erlotinib.

Main Methods:

• Human L-02 hepatic cells were treated with varying concentrations of erlotinib.
• Cytotoxicity was assessed after 72 hours.
• Apoptosis, nuclear morphology, caspase-3 activation, PARP cleavage, and mitochondrial function (Bcl-2/Bax ratio, mitochondrial membrane potential) were analyzed after 48 hours.

Main Results:

• Erlotinib induced dose-dependent cytotoxicity in L-02 cells.
• Erlotinib triggered apoptosis, characterized by nuclear morphological changes and activation of caspase-3 and PARP.
• Mitochondrial dysfunction was observed, including altered Bcl-2/Bax ratio and reduced mitochondrial membrane potential.

Conclusions:

• Erlotinib-induced hepatotoxicity in vitro appears to be mediated by apoptosis.
• The mitochondrial pathway plays a significant role in erlotinib-induced liver cell death.
• These findings support the development of hepatoprotectors targeting the mitochondrial apoptotic pathway.